Anakinra is a recombinant IL-1 receptor antagonist (IL-1Ra) that inhibits IL-1α and IL-β, and it has shown good effect in treating pustular psoriasis and deficiency in IL-1 receptor antagonist gene variants.493,494 Canakinumab is also an anti-IL-β antibody with good effects in GPP.495 Gevokizumab is another novel IL-1β antagonist, the effect of which has been preliminarily shown in a study, where two patients with GPP had 79% and 65% improvement in GPP score after 4 weeks of treatment.496 Therefore, IL-1 inhibitors may be effective in the treatment of psoriasis, especially GPP. The gene discussed is IL1A; the disease is psoriasis.